STOCK TITAN

Artivion (AORT) Form 4: CEO Disposes 12,500 Shares; Retains 852,783

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

James P. Mackin, President & CEO and director of Artivion, Inc. (AORT), reported a sale of common stock on 08/15/2025. The Form 4 shows he sold 12,500 shares at a weighted average price of $42.319 (prices ranged $42.25 to $42.585). After the transaction he beneficially owned 852,783 shares. The filing is signed 08/19/2025 and the reporting person notes availability of per-price sale details upon request.

Positive

  • Reporting compliance: The insider filed Form 4 with transaction date, amounts, price range, and signature, meeting disclosure requirements
  • Significant retained ownership: The reporting person still beneficially owns 852,783 shares, indicating continued substantial stake

Negative

  • Insider sale: The CEO sold 12,500 shares on 08/15/2025, which may be interpreted by some investors as a liquidity event
  • Price range disclosed but not per-lot detail: The filing provides a weighted average ($42.319) and range ($42.25–$42.585) but not the exact allocation at each price without request

Insights

TL;DR: CEO sold a small portion of holdings; retains a large ownership base of 852,783 shares.

The Form 4 discloses an open-market sale of 12,500 common shares on 08/15/2025 at a weighted average price of $42.319. The volume sold represents roughly 1.47% of the post-transaction beneficial holding level reported. Transaction codes indicate a standard sale; no derivatives or related-plan executions are reported. For investors, the transaction is a liquidity event by the insider but not a divestiture of a controlling position given the remaining stake.

TL;DR: Routine insider sale disclosed properly with price range noted and availability of detailed allocation on request.

The filing complies with Section 16 reporting: it lists the relationship (President & CEO and director), the transaction date, the number of shares sold, and a weighted average price with a disclosed price range. The signature and remark about providing per-price sale details on request increase transparency. There is no indication of Rule 10b5-1 plan reliance checked on the form.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mackin James P

(Last) (First) (Middle)
ARTIVION, INC.
1655 ROBERTS BLVD, NW

(Street)
KENNESAW GA 30144

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 S 12,500 D $42.319(1) 852,783 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects weighted average price. Range of prices were between $42.25 to $42.585. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Remarks:
/s/ James P. Mackin 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did James P. Mackin report on the Form 4 for AORT?

He reported a sale of 12,500 common shares on 08/15/2025 at a weighted average price of $42.319 and beneficial ownership of 852,783 shares following the sale.

When was the AORT insider transaction executed and filed?

Transaction date: 08/15/2025; Form signature date: 08/19/2025.

What price did the insider sell AORT shares at?

Weighted average sale price: $42.319; reported price range: $42.25 to $42.585.

Does the Form 4 indicate the sale was under a 10b5-1 plan?

No checkbox indicating a Rule 10b5-1 plan is marked in the provided content.

How much of his holding did the CEO sell?

He sold 12,500 shares, which is approximately 1.47% of the 852,783 shares reported as owned after the sale.
Artivion, Inc.

NYSE:AORT

AORT Rankings

AORT Latest News

AORT Latest SEC Filings

AORT Stock Data

2.19B
43.29M
4.5%
89.88%
2.32%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
KENNESAW